May 10, 2022 News by Marta Figueiredo, PhD B-cell-depleting Therapies May Increase Risk of Psoriasis Reports of psoriasis ā an autoimmune skin disease that shares some biological processes with multiple sclerosis (MS) ā are disproportionally high among MS patients on therapies that deplete B-cells, according to a U.S. study based on patient adverse event data. Conversely, patients on Tysabri (natalizumab), glatiramer acetate (sold…
June 24, 2021 News by Marisa Wexler, MS MS Symptoms Often Apparent Years Before Diagnosis Many people with multiple sclerosis (MS) start experiencingĀ symptoms of the disease several years before being diagnosed, a new study suggests. While it has long been known that people with MS tend to seek medical attention more frequently in the years before diagnosis than those without the disease, there…
February 6, 2020 News by Patricia Inacio, PhD Interleukin-17A Plays Key Role in Inflammation in MS, Mouse Study Finds The immune signaling molecule interleukin-17A (IL-17A) promotes the recruiting of inflammatory cells to the central nervous system (brain and spinal cord) in a multiple sclerosis (MS) mouse model, a study found. The findings support the potential of therapies that target IL-17 in MS. IL-17A is part of the IL-17…
November 2, 2018 News by Jose Marques Lopes, PhD Study Sheds New Light on Tecfidera’s Inhibitory Mechanism of Action Multiple sclerosis (MS) treatment Tecfidera (dimethyl fumarate) binds to a specific amino acid in key enzymes to inhibit their activity, according to a study that sheds more light on this therapy’s little-known mechanism of action. This newly identified regulatory mechanism may lead to the discovery of new compounds…
April 24, 2018 News by Marta Figueiredo, PhD Compound Produced by Immune Cells May Hold Promise for Multiple Sclerosis A compound produced by immune cells is able to treat psoriasis ā a skin disorder ā in mice, and may be effective against other autoimmune diseases, such as multiple sclerosis, according to a recent study. The study, āElectrophilic properties of itaconate and derivatives regulate the IĪŗBĪ¶āATF3 inflammatory…
August 4, 2017 Columns by John Connor Itchy Arms and the Internet: Making Rash Assumptions It’s been an incredibly bad few weeks, so I’m not surprised that I spent recent days wondering if I had incurable liver disease. Living with chronic illness, plus the internet, plus nowĀ justifiable hypochondria, is a very dark nexus. It started with a UTI thatĀ has been persistent for nigh…
February 5, 2016 News by Margarida Azevedo, MSc MS-related Inflammation May Be Reduced With Natural Protein, Study Shows In a new study using several mouse models of human immune-mediated inflammatory diseases, including multiple sclerosis (MS), researchers found that increased levels of an endogenous protein called tristetraprolin (TTP) resulted in protection against pro-inflammatory diseases. The results suggested that this natural protein might constitute a valuable therapeutic strategy to reduce…
December 4, 2015 News by Patricia Silva, PhD Brickell Biotech Targeting MS and Other Autoimmune Diseases Brickell Biotech, Inc., a pharmaceutical company developingĀ novel therapies in the field of dermatology, recently announced it has exclusive worldwide rights over a series of new, retinoic acid-related orphan nuclear receptor gamma (RORy) inhibitors from the New York University (NYU) and Orca Pharmaceuticals.Ā As part of the agreement, Brickell will be…
July 16, 2015 News by admin Study Shows Skin Problems Can Be Caused by Interferon-Ī² MS Therapy Skin problems may be caused by interferon-Ī², a common treatment for multiple sclerosis (MS), according to a new study published by a German research group at the Klinik und Poliklinik fĆ¼r Dermatologie, Venerologie und Allergologie, in WĆ¼rzburg, Germany. The work, entitled “Cutaneous Adverse Events Associated with Interferon-Ī²…